About Jade Biosciences Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate JADE101 targets the cytokine APRIL and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201 an afucosylated anti-BAFF-R monoclonal antibody as well as JADE301 an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics an antibody discovery engine founded by Fairmount. For more information visit JadeBiosciences.com and follow the Company on LinkedIn Role Overview Jade is developing potentially transformational disease-modifying therapies for people living with autoimmune diseases. With three biologics programs in the clinic and multiple ongoing studies from Phase I to Phase … Sign In to View